Genmab A/S - ESG Rating & Company Profile powered by AI
The webpage includes a questions and answers section on Genmab A/S. The ESG score includes 17 UN SDGs including: 'Clean Water & Sanitation', 'Decent Work & Economic Growth' and 'Peace, Justice & Strong Institutions'. The report of Genmab A/S incorporates data points from across the internet and also from available filings by Genmab A/S.
Genmab A/S in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.2; made up of an environmental score of 5.0, social score of 5.0 and governance score of 5.7.
5.2
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 658 | Transchem Ltd | 5.3 | High |
| 658 | Zenith Healthcare Ltd | 5.3 | High |
| 687 | Genmab A/S | 5.2 | High |
| 687 | Cardiol Therapeutics Inc | 5.2 | High |
| 687 | Cell Source Inc | 5.2 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Genmab A/S have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Genmab A/S disclose current and historical energy intensity?
Sign up for free to unlockDoes Genmab A/S report the average age of the workforce?
Sign up for free to unlockDoes Genmab A/S reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Genmab A/S disclose its ethnicity pay gap?
Sign up for free to unlockDoes Genmab A/S disclose cybersecurity risks?
Sign up for free to unlockDoes Genmab A/S offer flexible work?
Sign up for free to unlockDoes Genmab A/S have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Genmab A/S disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Genmab A/S conduct supply chain audits?
Sign up for free to unlockDoes Genmab A/S disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Genmab A/S conduct 360 degree staff reviews?
Sign up for free to unlockDoes Genmab A/S disclose the individual responsible for D&I?
Sign up for free to unlockDoes Genmab A/S disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Genmab A/S disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Genmab A/S disclose water use targets?
Sign up for free to unlockDoes Genmab A/S have careers partnerships with academic institutions?
Sign up for free to unlockDid Genmab A/S have a product recall in the last two years?
Sign up for free to unlockDoes Genmab A/S disclose incidents of discrimination?
Sign up for free to unlockDoes Genmab A/S allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Genmab A/S issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Genmab A/S disclose parental leave metrics?
Sign up for free to unlockDoes Genmab A/S disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Genmab A/S disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Genmab A/S disclose the pay ratio of women to men?
Sign up for free to unlockDoes Genmab A/S support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Genmab A/S disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Genmab A/S reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Genmab A/S involved in embryonic stem cell research?
Sign up for free to unlockDoes Genmab A/S disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Genmab A/S disclose its waste policy?
Sign up for free to unlockDoes Genmab A/S report according to TCFD requirements?
Sign up for free to unlockDoes Genmab A/S disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Genmab A/S disclose energy use targets?
Sign up for free to unlockDoes Genmab A/S disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Genmab A/S have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Genmab A/S
These potential risks are based on the size, segment and geographies of the company.
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.